CancerDrs

Prostate Cancer clinical trials in Oregon

26 actively recruiting prostate cancer trials at 14 sites across Oregon.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full prostate cancer transparency page →

Phase 3 Recruiting Network

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Oregon:
  • Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
  • Saint Charles Health System — Bend, Oregon
  • Clackamas Radiation Oncology Center — Clackamas, Oregon
  • Bay Area Hospital — Coos Bay, Oregon
  • Providence Hood River Memorial Hospital — Hood River, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Sites in Oregon:
  • Saint Charles Health System — Bend, Oregon
  • Clackamas Radiation Oncology Center — Clackamas, Oregon
  • Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
  • Bay Area Hospital — Coos Bay, Oregon
  • Legacy Mount Hood Medical Center — Gresham, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Oregon:
  • Legacy Mount Hood Medical Center — Gresham, Oregon
  • Legacy Good Samaritan Hospital and Medical Center — Portland, Oregon
  • Oregon Health and Science University — Portland, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07200830
Sites in Oregon:
  • Providence Portland Medical Center — Portland, Oregon
  • Providence Saint Vincent Medical Center — Portland, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 wit…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in Oregon:
  • Compass Oncology — Portland, Oregon
  • VA Portland Health Care System — Portland, Oregon
  • Oregon Urology Institute — Springfield, Oregon
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in Oregon:
  • Oregon Urology Institute — Springfield, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment

Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
NCT ID: NCT06520345
Sites in Oregon:
  • OHSU Knight Cancer Center — Portland, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing co…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05806515
Sites in Oregon:
  • Saint Alphonsus Medical Center-Baker City — Baker City, Oregon
  • Saint Charles Health System — Bend, Oregon
  • Clackamas Radiation Oncology Center — Clackamas, Oregon
  • Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
  • Bay Area Hospital — Coos Bay, Oregon
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

FOG-001 in Locally Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Oregon:
  • Oregon Health and Science University — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03972657
Sites in Oregon:
  • Providence Portland Medical Center — Portland, Oregon
  • Oregon Health & Science University (3485 S. Bond) — Portland, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

Sponsor: AstraZeneca
NCT ID: NCT05489211
Sites in Oregon:
  • Research Site — Portland, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therap…

Sponsor: VA Office of Research and Development
NCT ID: NCT05011383
Sites in Oregon:
  • VA Portland Health Care System, Portland, OR — Portland, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

The purpose of this study is to learn about how an investigational drug intervention completed before doing prostate surgery (specifically, radical prostatectomy with lymph node dissection) may help in treatment of high risk localized pros…

Sponsor: VA Office of Research and Development
NCT ID: NCT05593497
Sites in Oregon:
  • VA Portland Health Care System, Portland, OR — Portland, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for indiv…

Sponsor: University of Chicago
NCT ID: NCT05726292
Sites in Oregon:
  • Oregon Health & Science University — Portland, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

EMBRACE: Exercising Together

This phase II trial tests how well an exercise intervention, Exercising Together, works in preventing declines in physical and mental health in couples during radiation treatment for cancer. Treatments for cancer can cause side effects suc…

Sponsor: OHSU Knight Cancer Institute
NCT ID: NCT06049355
Sites in Oregon:
  • OHSU Knight Cancer Institute — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Oregon:
  • Exelixis Clinical Site #51 — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms

Sponsor: SystImmune Inc.
NCT ID: NCT07080242
Sites in Oregon:
  • Providence Cancer Institute — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of t…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06095089
Sites in Oregon:
  • Oregon Health And Science University — Portland, Oregon
View on ClinicalTrials.gov →
Recruiting NIH

Precision-Based Genomics in Prostate Cancer

Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and may affect…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04706663
Sites in Oregon:
  • Oregon Health Sciences University — Portland, Oregon
View on ClinicalTrials.gov →
Phase 4 Recruiting Industry

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

The impact of fluciclovine (18F) PET on the management of participants with prostate cancer following negative or equivocal PSMA PET Imaging at the time of biochemical recurrence

Sponsor: Blue Earth Diagnostics
NCT ID: NCT07569926
Sites in Oregon:
  • Oregon Health & Science University — Portland, Oregon
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE

This clinical trial tests the effectiveness of an online weight loss plus resistance training intervention (iLIVE) to decrease obesity and improve frailty in men with prostate cancer who received androgen deprivation therapy (ADT). Androge…

Sponsor: OHSU Knight Cancer Institute
NCT ID: NCT06011499
Sites in Oregon:
  • OHSU Knight Cancer Institute — Portland, Oregon
View on ClinicalTrials.gov →

Showing 25 of 26 trials with sites in Oregon. See all prostate cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19